文献速递神经康复骨科与运动康复疼痛康复

重复注射A型肉毒毒素联合综合管理在上肢痉挛中两年目标达成的纵向研究

Longitudinal goal attainment with integrated upper limb spasticity management including repeat injections of botulinum toxin A: Findings from the prospective, observational Upper Limb International Spasticity (ULIS-III) cohort study.
PubMed 文献 · J Rehabil Med · 2021-02-24

ULIS-III为前瞻性观察性队列研究,纳入14国1004例成人上肢痉挛患者,其中953例接受≥1个周期A型肉毒毒素注射(中位4周期)并完成目标达成量表评估。重复治疗周期中目标达成符合预期,2年累积目标达成量表T评分均值49.5(95%CI 49.1–49.9),痉挛、疼痛、不自主运动及主动/被动功能标准化测量均显著改善。

要点

  • 重复BoNT-A注射联合综合管理可在长达7个周期内维持目标达成量表变化评分≥10。
  • 被动功能相关主要目标达成率86.6%,高于主动功能相关目标的71.4%。
  • 多数患者注射后接受治疗师干预,最常见为被动牵伸(各周期70.1%–79.8%)。

核心结论

  • 该大型国际研究通过以患者为中心的目标达成和标准化测量,为2年内重复BoNT-A周期治疗的获益提供证据。

研究设计与样本

  • ULIS-III为前瞻性观察性队列研究,纳入14个国家1004例成人上肢痉挛患者,随访2年。
  • 953例接受≥1个周期BoNT-A注射(中位4周期)且完成≥1次目标达成量表评估。

主要发现

  • 重复周期中患者目标达成符合预期,2年累积目标达成量表T评分均值49.5(95%CI 49.1–49.9)。
  • 目标达成量表变化评分均值≥10在多达7个周期中得以维持。
  • 被动功能相关主要目标达成率86.6%,主动功能相关主要目标达成率71.4%。
  • 痉挛、疼痛、不自主运动、主动及被动功能的标准化测量在研究期间均显著改善。

关键数值与推荐

  • 第1–6周期中55.9%–64.6%的患者在BoNT-A治疗后接受治疗师干预。
  • 第1–6周期中最常见的治疗干预为被动牵伸,比例70.1%–79.8%。

临床怎么用

  • 上肢痉挛管理可考虑重复BoNT-A注射周期并联合治疗师干预(如被动牵伸),以促进以患者为中心的目标达成。
  • 设定目标时需注意主动功能相关目标的达成率可能低于被动功能相关目标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the longitudinal effects of integrated spasticity management incorporating repeated cycles of botulinum toxin A type A (BoNT-A) over 2 years. METHODS: The Upper Limb International Spasticity study was a prospective, observational, cohort study following adult patients over 2 years of integrated upper-limb spasticity management including repeat botulinum toxin (BoNT-A) treatment (any commercially-available product). RESULTS: A total of 1,004 participants from 14 countries were enrolled, of which 953 underwent ≥ 1 BoNT-A injection cycle (median 4 cycles) and had ≥ 1 goal attainment scaling assessment. Most participants (55.9-64.6% across cycles 1-6) saw a therapist after BoNT-A treatment; the most frequent therapy intervention was passive stretch (70.1-79.8% across cycles 1-6). Patients achieved their goals as expected over repeated cycles; mean cumulated goal attainment scaling T-score at 2 years was 49.5 (49.1, 49.9). Mean goal attainment scaling change scores of ≥ 10 were maintained across up to 7 cycles. Higher rates of goal achievement were seen for primary goals related to passive vs active function (86.6% vs 71.4% achievement). Standardized measures of spasticity, pain, involuntary movements, active and passive function improved significantly over the study. CONCLUSION: This large, international study provides evidence for benefit of repeated cycles of BoNT-A, over 2 years captured through person-centred goal attainment and standardized measures.

来源:J Rehabil Med,查看原文。版权归原作者所有。

引用

  1. Turner-Stokes L, Jacinto J, Fheodoroff K, et al. Longitudinal goal attainment with integrated upper limb spasticity management including repeat injections of botulinum toxin A: Findings from the prospective, observational Upper Limb International Spasticity (ULIS-III) cohort study. J Rehabil Med. 2021. PMID: 33616192. doi:10.2340/16501977-2801

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。